Sigma Healthcare (SIG) Shares Slide 5.5% on $10B Boots Acquisition Talks

Key Highlights

• Shares of Sigma Healthcare (SIG) tumbled up to 5.5% to A$2.76 following confirmation of exploratory acquisition discussions for Boots
• The potential transaction could exceed $10 billion in value, with Sigma facing competition from Canada’s Weston family
• Private equity firm Sycamore Partners, current owner of Boots, is evaluating potential sale options for the UK pharmacy giant operating over 1,800 locations
• A finalized acquisition would terminate Boots’ previously announced London stock market listing plans
• Sigma has established initial UK market presence through its collaboration with Greenlight Healthcare to launch Chemist Warehouse-branded locations across London

Shares of Sigma Healthcare (SIG) experienced a decline of up to 5.5% to A$2.76 on Wednesday following the Australian pharmaceutical retailer’s acknowledgment that it has initiated exploratory talks regarding a potential acquisition of British pharmacy giant Boots.

Sigma Healthcare Limited, SIG.AX

The potential acquisition, initially disclosed by the Financial Times, could see Boots valued at more than $10 billion. Sigma isn’t the sole contender pursuing the pharmacy chain — the Weston family from Canada, who maintain controlling interests in Loblaw, has also emerged as a competing bidder.

Sycamore Partners, a US-based private equity company, currently holds ownership of Boots. The pharmacy network maintains operations across more than 1,800 UK locations and has expanded to 11 nations, including Ireland, Mexico, and Thailand, with a combined retail footprint of 3,776 stores as of August last year.

Should the sale proceed to completion, Boots would abandon its proposed London stock exchange debut, the Financial Times has reported.

Sigma’s pursuit of Boots aligns with the company’s strategic expansion into global markets. Just last month, the Australian firm announced a strategic alliance with UK-based Greenlight Healthcare to introduce Chemist Warehouse-branded pharmacy locations throughout London while providing operational support including inventory systems and promotional strategies for Greenlight’s existing network of 22 pharmacies.

Chemist Warehouse Financial Muscle

The UK expansion effort enjoys substantial financial backing from prominent Australian business figures. Sigma’s principal shareholders include billionaire siblings Jack and Sam Gance alongside business associate Mario Verrochi — the founding team behind the Chemist Warehouse empire.

Verrochi commands a current net worth of $5.5 billion. Jack Gance holds assets valued at $3.4 billion, while Sam Gance’s wealth stands at $3.2 billion, based on Forbes tracking data.

Earlier this year in February 2025, Chemist Warehouse completed its merger with Sigma Healthcare, establishing a pharmaceutical retail powerhouse with a combined valuation surpassing $22 billion. The unified organization now operates a network exceeding 950 retail locations spanning Australia, China, Dubai, Ireland, and New Zealand.

Implications of a Boots Acquisition for Sigma

Acquiring Boots represents far more than a modest expansion opportunity. With approximately 3,800 stores worldwide and franchise partnerships extending into the Middle East and Indonesia, this transaction would fundamentally reshape Sigma’s business profile.

The company has not revealed specific financial details regarding its proposed offer, nor has it indicated whether external financial partners are involved in structuring a transaction of this magnitude.

Wednesday’s market response demonstrates investor skepticism. A deal exceeding $10 billion would dwarf any previous transaction undertaken by the organization, and the likelihood of completion remains highly uncertain.

Sigma indicated it would provide further market updates should any significant developments occur.

The post Sigma Healthcare (SIG) Shares Slide 5.5% on $10B Boots Acquisition Talks appeared first on Blockonomi.